{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:54:45Z","timestamp":1793382885896,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Rheumatic disease\n                      <jats:bold>-<\/jats:bold>\n                      associated macrophage activation syndrome (RD-MAS) is a rare and life-threatening complication of rheumatic diseases, with approximately 30% of cases being refractory to conventional therapeutic protocols. Ruxolitinib, a Janus kinase 1\/2 inhibitor, has emerged as a potential therapy for refractory RD-MAS. This study aimed to evaluate its efficacy and safety in patients with refractory RD-MAS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A meticulous chart review was conducted on 20 refractory RD-MAS patients treated with ruxolitinib. Data from no ruxolitinib treatment RD-MAS patients served as historical controls. Clinical and laboratory parameters, therapeutic response, and survival outcomes were analyzed. Ruxolitinib\u2019s efficacy and safety were evaluated, and survival rates were compared to historical controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 20 refractory RD-MAS patients (17 females, 3 males) with underlying conditions: adult-onset Still\u2019s disease (n = 13), systemic lupus erythematosus (n = 4), and other connective tissue diseases (CTDs) (n = 3). All patients displayed active disease at baseline. By week 8, 50% (10\/20) of patients achieved partial remission, while 30% (6\/20) attained complete remission. The ruxolitinib group had a significantly higher survival rate (19\/20, 95%) compared to historical controls (13\/21, 62%) (P = 0.011). By week 8, the median daily glucocorticoid dose dropped from 2.7 mg\/kg to 0.5 mg\/kg. Cytomegalovirus infection occurred in 20% (4\/20) of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ruxolitinib demonstrated substantial efficacy and tolerability in refractory RD-MAS, improving clinical outcomes and reducing glucocorticoid dependence. Although limited by its retrospective nature and small cohort size, this study suggests that ruxolitinib may serve as a potential therapy for refractory RD-MAS, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1604648","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:10:13Z","timestamp":1750896613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingjing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B3","article-title":"Adult hemophagocytic lymphohistiocytosis: a Review","volume":"115","author":"Yildiz","year":"2020","journal-title":"QJM"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06184-1","article-title":"Short-term, low-dose etoposide in refractory adult-onset Still\u2019s disease-associated macrophage activation syndrome","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in hemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae124","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy","volume":"63","author":"Ulu","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis: an open-label, single-center, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2022.29.2.123","article-title":"A case of macrophage activation syndrome during the treatment of adult-onset still\u2019s disease with tocilizumab","volume":"29","author":"Lee","year":"2022","journal-title":"J Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2022.21064","article-title":"Ruxolitinib for refractory macrophage activation syndrome complicating adult-onset still\u2019s disease","volume":"9","author":"Levy","year":"2022","journal-title":"Eur J Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19803","article-title":"Ruxolitinib-based regimen in children with autoimmune disease or autoinflammatory disease-related hemophagocytic lymphohistiocytosis","volume":"206","author":"Fang","year":"2025","journal-title":"Br J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"112451","DOI":"10.1016\/j.intimp.2024.112451","article-title":"The efficacy and safety of JAK inhibitors in patients with adult-onset still\u2019s disease: A meta-analysis and systematic review","volume":"137","author":"Liao","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024362","article-title":"Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome","author":"Ma","year":"2025","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2010.03.011","article-title":"Serum ferritin: Past, present and future","volume":"1800","author":"Wang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00008.2013","article-title":"Systemic iron homeostasis","volume":"93","author":"Ganz","year":"2013","journal-title":"Physiol Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:10:13Z","timestamp":1750896613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1604648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1604648"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1604648","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"article-number":"1604648"}}